Previous research posits that the abundance of peripheral CD4+ T cells may prognosticate outcomes in patients afflicted with gastrointestinal tumors [30] and is closely associated with the efficacy of immunotherapy [31]. This evidence concerns the gene CD4 and digestive system neoplasm.